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Summary
Objectives: Resistance to antiepileptic drugs has occurres in some patients. The aim of this study was to evaluate the patients with refractory 
partial epilepsy who initially responded to levetiracetam (LEV) add-on therapy and who had the seizure frequency return to their baseline 
after a honeymoon period.
Methods: Seven patients with refractory epilepsy, who had transient seizure control with LEV add-on therapy, were included in this study. 
Age, sex, detailed medical history, epilepsy duration, seizure frequency, concomitant AEDs, time to seizure occurrence after the initiation of 
LEV, side effects of LEV, cranial magnetic resonance imaging (MRI) and electroencephalography (EEG) data were collected for each patient.
Results: Mean age was 26.14±5.14 years. Three patients were male and the other four were female. Mean seizure frequency before LEV tre-
atment was 8.71±5.25 /month. The seizure-free days with levetiracetam add-on therapy was 51-82 days. After the honeymoon effect, seizure 
frequency returned to the baseline level and did not changed despite an increase in dosage. Cranial MRI was normal in two patients, while 
interictal EEG was normal in two patients.
Conclusion: The resistance to LEV add-on treatment in patients with refractory partial onset seizures may develop, but the honeymoon effect 
of LEV was longer in our patients when compared to the drug’s literature.
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Özet
Amaç: Antiepileptik ilaç tedavisine direnç bazı hastalarda görülebilmektedir. Bu çalışmanın amacı başlangıçta levetirasetam (LEV) ekleme 
tedavisine yanıt veren ve balayı periyodu sonrası nöbet frekansı başlangıç düzeyine gelen hastaları değerlendirmektedir. 
Gereç ve Yöntem: Geçici olarak levetirasetam ekleme tedavisiyle nöbet kontrolü sağlanan refrakter epilepsili yedi hasta çalışmaya alındı. 
Her bir hasta için yaş, cinsiyet, ayrıntılı tıbbi özgeçmiş, epilepsi süresi, nöbet frekansı, kullanılan antiepileptik ilaçlar, LEV başlandıktan sonra 
nöbet görülünceye kadar geçen süre, LEV yan etkileri, kraniyal manyetik rezonans görüntüleme (MRG) ve elektroensefalografi (EEG) verileri 
gözden geçirildi. 
Bulgular: Ortalama yaş 26.14±5.14 yıl idi. Üç hasta erkek ve diğerleri kadındı. LEV tedavisi öncesi ortalama nöbet sayısı 8.71±5.25/aydı. Le-
vetirasetam ekleme tedavisi sonrası nöbetsiz gün sayısı  51-82 gündür. Balayı dönemi sonrası nöbet frekansı önceki haline döndü. Bu frekans 
doz artımına ragmen değişmedi. İnteriktal EEG iki hastada normalken kraniyal MRG iki hastada normal bulundu.
Sonuç: Refrakter parsiyel başlangıçlı nöbetlerde LEV ekleme tedavisine direnç gelişebilir, fakat bizim hastalarımızda LEV balayı etkisi ilaç 
literatürüyle karşılaştırıldıgında daha uzundur.
Anahtar sözcükler: Levetirasetam; parsiyel nöbetler; epilepsi; sık nöbetler; ilaç direnci. 
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ORIGINAL ARTICLE / KLİNİK ÇALIŞMAIntroduction
Epilepsy is one of the most common neurological disor-
ders and it affects about 1% of population.[1] This chronic 
condition is often difficult to treat because 20-30% of the 
patients have a refractory form.[2] Standard antiepileptic 
drug (AED) therapy does not provide optimal manage-
ment for these patients; therefore, new AEDs are needed. 
Levetiracetam (LEV), one of the recently introduced AEDs, 
is the S-enantiomer of α-ethyl-2-oxo-1-pyrrolidine acet-
amide.[3] LEV appears to have unique mechanism of ac-
tion[4] that acts by binding to and modulating the synaptic 
vesicle protein SV2A.[5] It received FDA approval in Novem-
ber 1999 as adjunctive treatment for adults with partial-
onset seizures[6] and has been subject to several clinical 
trials since then.[3,7-9]
LEV is rapidly and almost completely absorbed following 
oral administration. It exhibits linear pharmacokinetics 
and the likelihood of accumulation in the body is rare.[10] 
It is eliminated entirely through renal excretion and, drug 
interaction potential is absent or negligible[11] because its 
pharmacokinetics profile includes minimal protein bind-
ing and lack of hepatic metabolism (not cytocrome P450 
dependent).[12] The LEV tolerability profile regarding the ef-
fects on memory and cognitive function are also good.[13] 
LEV is administered twice daily and can be initiated twice 
daily, and reaches a steady state after two days.[10]
 
LEV is efficient in controlling seizures from the first week of 
drug initiation, during up-titration and throughout the first 
months of treatment.[14] Some epilepsy patients rapidly de-
velop resistance to AED. LEV resistance was also reported 
in some cases.[15] In the present study, we have evaluated 
the patients with refractory partial epilepsy who initially 
responded to add-on LEV therapy, but after its use had 
their seizure frequency return to the initial level. 
Materials and Methods 
Seven patients with refractory epilepsy, who had transient 
seizure control with LEV add-on therapy, were included 
in this study. All seven patients initially responded to LEV 
treatment, but then had their seizure frequency return 
to baseline after a period of time. They were followed up 
in the Epilepsy Unit of the Ankara Research and Training 
Hospital between December 2004 and February 2008. Age, 
sex, detailed medical history, epilepsy duration, seizure 
frequency, concomitant AED’s, time to seizure occurrence 
after the initiation of LEV, and side effects of LEV were col-
lected for each patient. Electroencephalography (EEG) and 
cranial magnetic resonance imaging (MRI) were also inves-
tigated. Seizure frequency was determined using a seizure 
diary completed by each patient or caregiver.
Patients signed an informed consent form before their 
treatment. LEV was given at a dose of 500 mg twice daily 
(1000 mg/day) as an add-on therapy. The dosage of LEV 
was increased gradually to a maximum of 3000 mg/day 
when the seizures recurred.
Statistical analysis was carried out using the Statistical 
Package for Social Sciences (SPSS 11.0 for Windows; SPSS, 
USA). The results of descriptive analysis were expressed 
mean±SD or number of cases and percentage.
Results
Demographic data, seizure frequency, duration of epilepsy, 
interictal EEG, ictal EEG and cranial MRI findings are sum-
marized in Table 1. Mean age was 26.14±5.14 (Age range: 
20-33). Three (42.9%) of these patients were male and 
the other four (57.1%) were female. Mean partial seizure 
frequency before LEV treatment was 8.71±5.25 /month 
(range: 5-20/month). Average duration of the patients’ epi-
lepsy was 13.28±5.34 years. The mean number of concomi-
tant antiepileptic medication except LEV was 2.57±0.53. 
The most common AEDs used by the patients were sodium 
valproate and carbamezapine followed by lamotrigine. 
The mean seizure-free day with LEV add-on therapy was 
64.00±10.28 (range 51-82). After this period, the frequency 
of seizures returned to baseline level. Seizure frequency 
did not changed, although LEV was increased in two suc-
cessive doses as 2000 and 3000 mgs/day. One patient had 
vertigo and dizziness, a side effect attributed to LEV. The 
treatment was not stopped since those effects were mild 
and disappeared within one week.
Cranial MRIs revealed changes indicating right hippocam-
pal atrophy in three patients. The remaining four patients 
had normal cranial MRI. Interictal EEG was normal in two 
patients. Four patients underwent long term video-EEG 
monitoring. Ictal activity was determined in two of them. 
One had seizures originating from right mesial temporal re-
gion. She was a surgical candidate. The other patient with 
ictal EEG findings had bi-temporal epilepsy and she was 
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not suitable for surgery. Origin of the ictal focus could not 
be determined in the remaining. 
Discussion
In this article, we report patients with partial seizures, who 
responded to LEV add-on treatment initially. AED resis-
tance developed 51-82 days later. A similar return to the 
baseline seizure frequency after an initial response to an 
add-on AED during the first month of treatment was re-
ported by Boggs et al.[16] for several AEDs including carba-
mazepine, phenytoin, lamotrigine and gabapentine. Resis-
tance to LEV treatment was also reported previously.[15,17,18] 
Glien et al.[17] have tested LEV in a rat model of temporal 
lobe epilepsy with spontaneous recurrent seizures. They 
separately investigated the effect of LEV for the first and 
second week of treatment and found that the significant 
anticonvulsant effect determined in the first week was 
partially diminished in the second week. They suggested 
that tolerance might have developed in some rats. Another 
study in amygdala-kindled rats showed mild reduction in 
the anticonvulsant effect of LEV after three weeks of treat-
ment.[18]
In the literature, a case with daily seizures and resistance to 
LEV treatment was reported by Friedman and French.[15] The 
patient was initially responding to LEV add-on treatment, 
but this effect was transient and seizure frequency returned 
to the baseline after one week. They recommended LEV 
once weekly and found that the patient had significantly 
fewer seizures on the day of and after administration. They 
suggested intermittent LEV therapy was a useful treatment 
strategy for patients with refractory epilepsy who have de-
veloped resistance to AEDs .[15]
The mechanism of LEV resistance is not known. Accord-
ing to the literature, the resistance develops quickly.[15,17,18] 
A previous study showed that LEV acts by binding to and 
modulating the synaptic vesicle protein SV2A.[5] We do not 
know how LEV exerts its antiepileptic effects by interacting 
with this protein. Long-term LEV exposure may alter the 
chemical structure of protein; this may explain why some 
patients become resistant to long-term LEV therapy.
 
In our patients, the resistance to LEV add-on treatment oc-
curred 51-82 days later, a period longer than that reported 
Table 1. Demographic data, seizure frequency, duration of epilepsy, interictal EEG, ictal EEG and cranial MRI findings
Age/  Epilepsy  Partial  Other AED (mg/day)  Seizure  Kranial    Interictal  Ictal EEG
Sex  duration  seizure    free day  MRI    EEG 
  (year)  (freq/month)    after LEV
20/F  19  8  Sodium valproate 1500   63  R hippocampal  R temporal  R mesial
      Carbamezapine 1000      atrophy  sharp waves  temporal
      Lamotrigine 200
33/M  9  6  Sodium valproate 1500   71  Normal  Bitemporal  –
      Carbamezapine 1200        sharp waves
      Lamotrigine 200 
28/M  11  6  Sodium valproate 1500   61  Normal  R>L bilateral  –
      Carbamezapine 1200        centrotemporal
              sharp waves
22/F  19  6  Oxcarbazepine  1800    82  Normal  R temparoparietal  –
      Sodium valproate 1500       sharp wave
28/F  17  10  Sodium valproate 1500   65  R hippocampal  R>L bilateral  Bitemporal
      Carbamezapine 1200        atrophy  temporal
              sharp waves
31/M  13  20  Sodium valproate 1500   51  Normal  Normal  No lateralization
      Carbamezapine 1200           and localization
      Lamotrigine 200
21/F  5  5  Carbamezapine 1200 
      Lamotrigine 400    55  R hippocampal  Normal  R hemisphere
           atrophy
F: Female; M: Male; R: Right; L: Left.18
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in the drug’s literature. The honeymoon effect was mainly 
observed in the first month[16] and LEV resistance appeared 
in rats after the first[17] and third[18] weeks of treatment. We 
cannot explain why our patients had a longer honeymoon 
period. However, hereditary factors may be responsible for 
this variation. Intermittent LEV therapy was not given to our 
patients, because our patients could not predict their sei-
zures and/or their seizures’ frequencies were not in regular 
intervals.
In our study, one patient had right temporal lobe epilepsy 
and another had bilateral temporal lobe epilepsy when we 
investigated their ictal EEG. The seizure semiology of the 
remaining two patients, who had ictal EEG, were mainly 
extra-temporal, although certain localization and/or later-
alization could not be made. Three patients did not under-
go video-EEG monitoring. However, the seizure semiology 
and interictal EEG suggested temporal lobe epilepsy.
In conclusion, although LEV provides efficient control as an 
add-on drug in the treatment of certain intractible partial 
epileptic seizures early positive response may be reversible 
in some cases even in maximum therapeutic doses.
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